Norovirus VLP
Norovirus virus-like particles (NoV VLPs) are non-infectious, self-assembled protein structures that mimic the morphology and antigenicity of the norovirus capsid without containing the viral RNA. Noroviruses are highly contagious viruses that cause acute gastroenteritis globally. NoV VLPs are a promising platform for developing vaccines, diagnostics, and therapeutics against norovirus infections.
Structure of Norovirus VLPs
Norovirus VLPs are composed of the major structural protein:
- Capsid Protein VP1: Self-assembles into icosahedral particles, mimicking the native virus. VP1 has two domains:
- Shell (S) Domain: Forms the structural backbone of the particle.
- Protruding (P) Domain: Extends outward and contains the receptor-binding sites, making it the primary target for neutralizing antibodies.
- Minor Capsid Protein VP2: Sometimes included to enhance particle stability and assembly.
Production Systems
NoV VLPs are produced in various expression systems, depending on scalability and functionality:
- Insect Cells: Baculovirus expression systems are widely used for high-yield production of functional VLPs.
- Yeast Systems: Cost-effective and scalable, frequently used for commercial VLP-based vaccines.
- Mammalian Cells: Enable accurate glycosylation and post-translational modifications, closely resembling native virus structures.
Applications
- Vaccines
- Prophylactic Vaccines: NoV VLP-based vaccines aim to induce robust neutralizing antibody responses to protect against multiple norovirus genotypes.
- Diagnostics
- Norovirus VLPs are used as antigens in serological assays to detect antibodies against noroviruses, aiding in epidemiological surveillance and outbreak investigation.
- Immunological Research
- Serve as tools for studying norovirus-host interactions and immune response mechanisms, particularly receptor binding and neutralization.
Norovirus virus-like particles are a promising tool for preventing and managing norovirus infections through vaccines, diagnostics, and immunological studies. With ongoing advancements in VLP technology, NoV VLP-based vaccines are expected to become a key component in controlling this globally prevalent pathogen, improving public health outcomes, and reducing the burden of gastroenteritis.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|